A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes
- Resource Type
- Article
- Authors
- Zeidan, Amer M. ; Boss, Isaac; Beach, C.L.; Copeland, Wilbert B.; Thompson, Ethan; Fox, Brian A.; Hasle, Vanessa E.; Ogasawara, Ken; Cavenagh, James; Silverman, Lewis R.; Voso, Maria Teresa; Hellmann, Andrzej; Tormo, Mar; O'Connor, Tim; Previtali, Alessandro; Rose, Shelonitda; Garcia-Manero, Guillermo
- Source
- In Blood Advances 12 April 2022 6(7):2207-2218
- Subject
- Language
- ISSN
- 2473-9529